<?xml version='1.0' encoding='utf-8'?>
<document id="29375383"><sentence text="Human UDP-Glucuronosyltransferase 2B4 and 2B7 Are Responsible for Naftopidil Glucuronidation in Vitro."><entity charOffset="66-76" id="DDI-PubMed.29375383.s1.e0" text="Naftopidil" /></sentence><sentence text="Naftopidil (NAF) is widely used for the treatment of benign prostatic hyperplasia and prevention of prostate cancer in elderly men"><entity charOffset="0-10" id="DDI-PubMed.29375383.s2.e0" text="Naftopidil" /><entity charOffset="12-15" id="DDI-PubMed.29375383.s2.e1" text="NAF" /><pair ddi="false" e1="DDI-PubMed.29375383.s2.e0" e2="DDI-PubMed.29375383.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29375383.s2.e0" e2="DDI-PubMed.29375383.s2.e1" /></sentence><sentence text=" These patients receive a combination of drugs, which involves high risk for drug-drug interaction" /><sentence text=" NAF exhibits superior efficacy but must be administered at a much higher dosage than other therapeutic drugs"><entity charOffset="1-3" id="DDI-PubMed.29375383.s4.e0" text="NAF" /></sentence><sentence text=" We previously showed that extensive glucuronidation of NAF enantiomers caused poor bioavailability"><entity charOffset="56-58" id="DDI-PubMed.29375383.s5.e0" text="NAF" /></sentence><sentence text=" However, the metabolic pathway and mechanism of action of NAF enantiomer remain to be elucidated"><entity charOffset="59-61" id="DDI-PubMed.29375383.s6.e0" text="NAF" /></sentence><sentence text=" The present study was performed to identify the human UDP-glucuronosyltransferases (UGTs) responsible for the glucuronidation of NAF enantiomers and to investigate the potential inhibition of UGT activity by NAF"><entity charOffset="130-132" id="DDI-PubMed.29375383.s7.e0" text="NAF" /><entity charOffset="209-211" id="DDI-PubMed.29375383.s7.e1" text="NAF" /><pair ddi="false" e1="DDI-PubMed.29375383.s7.e0" e2="DDI-PubMed.29375383.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29375383.s7.e0" e2="DDI-PubMed.29375383.s7.e1" /></sentence><sentence text=" The major metabolic sites examined were liver and kidney, which were compared with intestine" /><sentence text=" Screening of 12 recombinant UGTs showed that UGT2B7 primarily contributed to the metabolism of both enantiomers" /><sentence text=" Moreover, enzyme kinetics for R(+)-NAF, UGT2B7 (mean Km, 21 μM; mean Vmax, 1043 pmol/min/mg) showed significantly higher activity than observed for UGT2B4 and UGT1A9"><entity charOffset="31-39" id="DDI-PubMed.29375383.s10.e0" text="R(+)-NAF" /><entity charOffset="36-43" id="DDI-PubMed.29375383.s10.e1" text="NAF" /><pair ddi="false" e1="DDI-PubMed.29375383.s10.e0" e2="DDI-PubMed.29375383.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29375383.s10.e0" e2="DDI-PubMed.29375383.s10.e1" /></sentence><sentence text=" UGT2B4 (mean Km, 55 μM; mean Vmax, 1976 pmol/min/mg) and UGT2B7 (mean Km, 38 μM; mean Vmax, 1331 pmol/min/mg) showed significantly higher catalysis of glucuronidation of S(-)-NAF than UGT1A9"><entity charOffset="171-179" id="DDI-PubMed.29375383.s11.e0" text="S(-)-NAF" /><entity charOffset="176-183" id="DDI-PubMed.29375383.s11.e1" text="NAF" /><pair ddi="false" e1="DDI-PubMed.29375383.s11.e0" e2="DDI-PubMed.29375383.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29375383.s11.e0" e2="DDI-PubMed.29375383.s11.e1" /></sentence><sentence text=" In human liver microsomes, R(+)-NAF and S(-)-NAF also inhibited UGT1A9: mean Ki values for R(+)-NAF and S(-)-NAF were 10"><entity charOffset="28-36" id="DDI-PubMed.29375383.s12.e0" text="R(+)-NAF" /><entity charOffset="41-49" id="DDI-PubMed.29375383.s12.e1" text="S(-)-NAF" /><entity charOffset="92-100" id="DDI-PubMed.29375383.s12.e2" text="R(+)-NAF" /><entity charOffset="105-113" id="DDI-PubMed.29375383.s12.e3" text="S(-)-NAF" /><entity charOffset="33-40" id="DDI-PubMed.29375383.s12.e4" text="NAF" /><entity charOffset="46-53" id="DDI-PubMed.29375383.s12.e5" text="NAF" /><entity charOffset="97-104" id="DDI-PubMed.29375383.s12.e6" text="NAF" /><entity charOffset="110-117" id="DDI-PubMed.29375383.s12.e7" text="NAF" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e0" e2="DDI-PubMed.29375383.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e0" e2="DDI-PubMed.29375383.s12.e4" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e0" e2="DDI-PubMed.29375383.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e0" e2="DDI-PubMed.29375383.s12.e5" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e0" e2="DDI-PubMed.29375383.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e0" e2="DDI-PubMed.29375383.s12.e6" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e0" e2="DDI-PubMed.29375383.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e0" e2="DDI-PubMed.29375383.s12.e7" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e4" e2="DDI-PubMed.29375383.s12.e4" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e4" e2="DDI-PubMed.29375383.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e4" e2="DDI-PubMed.29375383.s12.e5" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e4" e2="DDI-PubMed.29375383.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e4" e2="DDI-PubMed.29375383.s12.e6" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e4" e2="DDI-PubMed.29375383.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e4" e2="DDI-PubMed.29375383.s12.e7" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e1" e2="DDI-PubMed.29375383.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e1" e2="DDI-PubMed.29375383.s12.e5" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e1" e2="DDI-PubMed.29375383.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e1" e2="DDI-PubMed.29375383.s12.e6" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e1" e2="DDI-PubMed.29375383.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e1" e2="DDI-PubMed.29375383.s12.e7" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e5" e2="DDI-PubMed.29375383.s12.e5" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e5" e2="DDI-PubMed.29375383.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e5" e2="DDI-PubMed.29375383.s12.e6" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e5" e2="DDI-PubMed.29375383.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e5" e2="DDI-PubMed.29375383.s12.e7" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e2" e2="DDI-PubMed.29375383.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e2" e2="DDI-PubMed.29375383.s12.e6" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e2" e2="DDI-PubMed.29375383.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e2" e2="DDI-PubMed.29375383.s12.e7" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e6" e2="DDI-PubMed.29375383.s12.e6" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e6" e2="DDI-PubMed.29375383.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e6" e2="DDI-PubMed.29375383.s12.e7" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e3" e2="DDI-PubMed.29375383.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29375383.s12.e3" e2="DDI-PubMed.29375383.s12.e7" /></sentence><sentence text="0 μM and 11" /><sentence text="5 μM, respectively" /><sentence text=" These data indicate that UGT2B7 was the principal enzyme mediating glucuronidation of R(+)-NAF and S(-)-NAF"><entity charOffset="87-95" id="DDI-PubMed.29375383.s15.e0" text="R(+)-NAF" /><entity charOffset="92-99" id="DDI-PubMed.29375383.s15.e1" text="NAF" /><entity charOffset="105-112" id="DDI-PubMed.29375383.s15.e2" text="NAF" /><pair ddi="false" e1="DDI-PubMed.29375383.s15.e0" e2="DDI-PubMed.29375383.s15.e0" /><pair ddi="false" e1="DDI-PubMed.29375383.s15.e0" e2="DDI-PubMed.29375383.s15.e1" /><pair ddi="false" e1="DDI-PubMed.29375383.s15.e0" e2="DDI-PubMed.29375383.s15.e2" /><pair ddi="false" e1="DDI-PubMed.29375383.s15.e1" e2="DDI-PubMed.29375383.s15.e1" /><pair ddi="false" e1="DDI-PubMed.29375383.s15.e1" e2="DDI-PubMed.29375383.s15.e2" /></sentence><sentence text=" UGT2B4 plays the key role in the stereoselective metabolism of NAF enantiomers"><entity charOffset="64-66" id="DDI-PubMed.29375383.s16.e0" text="NAF" /></sentence><sentence text=" R(+)-NAF and S(-)-NAF may inhibit UGT1A9"><entity charOffset="1-9" id="DDI-PubMed.29375383.s17.e0" text="R(+)-NAF" /><entity charOffset="14-22" id="DDI-PubMed.29375383.s17.e1" text="S(-)-NAF" /><entity charOffset="6-13" id="DDI-PubMed.29375383.s17.e2" text="NAF" /><entity charOffset="19-26" id="DDI-PubMed.29375383.s17.e3" text="NAF" /><pair ddi="false" e1="DDI-PubMed.29375383.s17.e0" e2="DDI-PubMed.29375383.s17.e0" /><pair ddi="false" e1="DDI-PubMed.29375383.s17.e0" e2="DDI-PubMed.29375383.s17.e2" /><pair ddi="false" e1="DDI-PubMed.29375383.s17.e0" e2="DDI-PubMed.29375383.s17.e1" /><pair ddi="false" e1="DDI-PubMed.29375383.s17.e0" e2="DDI-PubMed.29375383.s17.e3" /><pair ddi="false" e1="DDI-PubMed.29375383.s17.e2" e2="DDI-PubMed.29375383.s17.e2" /><pair ddi="false" e1="DDI-PubMed.29375383.s17.e2" e2="DDI-PubMed.29375383.s17.e1" /><pair ddi="false" e1="DDI-PubMed.29375383.s17.e2" e2="DDI-PubMed.29375383.s17.e3" /><pair ddi="false" e1="DDI-PubMed.29375383.s17.e1" e2="DDI-PubMed.29375383.s17.e1" /><pair ddi="false" e1="DDI-PubMed.29375383.s17.e1" e2="DDI-PubMed.29375383.s17.e3" /></sentence><sentence text=" Understanding the metabolism of NAF enantiomers, especially their interactions with metabolic enzymes, will help to elucidate potential drug-drug interactions and to optimize the administration of this medicine"><entity charOffset="33-35" id="DDI-PubMed.29375383.s18.e0" text="NAF" /></sentence><sentence text="" /></document>